Pipeline Highlights: AAT Ph2/3 Trial Design, AAT and HBV EASL Presentations, Dosing Starts in ARO-ANG3/APOC3 Ph 1s Arrowhead Pharmaceuticals (ARWR) continues to make rapid progress across most of ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 2 clinical study of ARC-AAT, an investigational RNAi-based medicine for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results